Global contract development and manufacturing organisation (CDMO), Recipharm, has today announced the acquisition of GenIbet, a Portuguese CDMO, specialising in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome. The acquisition forms part of Recipharm’s strategy to grow in the Biologics market, with a particular focus on drug substance manufacturing of novel ATMPs. GenIbet currently works with customer projects in the preclinical and Phase 1 stages and has a track record of developing novel production processes. Through its relationship with not-for-profit research organisation Ibet, the CDMO offers deep scientific expertise and novel
The post Recipharm acquires GenIbet to bolster Biologics offering appeared first on Pharma Mirror Magazine.
